survodutide
Peptide
Also known as BI 456906
Evidence outlook · lead readout
SYNCHRONIZE-1 (NCT06066515) · Obesity
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
SYNCHRONIZE-1 (NCT06066515): This was a randomized, double-blind, placebo-controlled Phase 3 trial in 725 adults with obesity without diabetes, with co-primary clinical weight-loss endpoints at Week 76. In the published primary analysis (treatment-regimen estimand, which counts early discontinuation and other obesity medicines), mean weight change was -13.0% with 6.0 mg and -12.2% with 3.6 mg versus -5.4% with placebo, and 71.9% and 72.6% versus 46.3% of participants reached at least 5% weight reduction (P<0.001 for all comparisons).
Also in development:Type 2 Diabetes · Phase 3MASH / NASH · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06077864 NCT06077864 · Obesity The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available. Registry: NCT06077864 | 3 | Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate non-inferiority) (up to Week 114) 2026-06-01 | Results not posted; external-source review pending | Partial signal | link ↗ |
View 4 more trials
SYNCHRONIZE-2 NCT06066528 · Obesity, Diabetes Mellitus, Type 2 This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in adults with obesity and type 2 diabetes (755 enrolled on the registry, 752 randomized in the publication), with co-primary clinical weight-loss endpoints at Week 76. The published primary analysis (treatment-regimen estimand) shows both co-primary endpoints met: mean weight change of -9.8% with 6.0 mg and -8.2% with 3.6 mg versus -3.9% with placebo, and 64.5% and 57.6% versus 35.1% of participants reached at least 5% weight reduction (P<0.001 for all comparisons). Registry: NCT06066528 | 3 | Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76) 2025-12-12 | Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo). | Partial signal | link ↗ |
SYNCHRONIZE-1 NCT06066515 · Obesity This was a randomized, double-blind, placebo-controlled Phase 3 trial in 725 adults with obesity without diabetes, with co-primary clinical weight-loss endpoints at Week 76. In the published primary analysis (treatment-regimen estimand, which counts early discontinuation and other obesity medicines), mean weight change was -13.0% with 6.0 mg and -12.2% with 3.6 mg versus -5.4% with placebo, and 71.9% and 72.6% versus 46.3% of participants reached at least 5% weight reduction (P<0.001 for all comparisons). Registry: NCT06066515 | 3 | Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76) 2025-12-02 | Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). | Reliable signal | link ↗ |
NCT06214741 NCT06214741 · Obesity, Overweight The study randomly assigned 307 participants to two survodutide doses or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoints were clinical weight-loss measures at Week 52, but no results or statistical comparisons are posted, so the outcome cannot yet be assessed. Registry: NCT06214741 | 3 | Percentage change in body weight from baseline to Week 52 (At baseline and at Week 52.); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52 (At baseline and at Week 52.) 2025-07-29 | Results not posted; external-source review pending | Partial signal | link ↗ |
SYNCHRONIZEJP NCT06176365 · Obesity Registry: NCT06176365 | 3 | Percentage change in body weight from baseline to Week 76 (at baseline, at week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (at baseline, at week 76) 2025-12-03 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other GLP-1/glucagon receptor (dual) drugs
mazdutide, pemvidutide, AZD9550, efinopegdutide, Zabopegdutide and 3 more. Compare all 9 GLP-1/glucagon receptor (dual) drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for MASH / NASH: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Survodutide: this drug | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Reliable signal | NCT06309992: Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. | |
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | Partial signal | NCT03900429: Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1). | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | not yet graded | No reviewed efficacy summary in this indication | |
| Aramchol | Phase 3 | — | Stearoyl-CoA desaturase 1 (SCD1) | not yet graded | No reviewed efficacy summary in this indication | |
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | Weak signal | Featured results are safety only in this race | |
| Lanifibranor | Phase 3 | Small molecule | Peroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Pegozafermin | Phase 3 | Protein / enzyme therapeutic | FGFR1c/2c/3c–β-Klotho agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT05989711: Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26). | |
| Belapectin | Phase 2/3 | Polysaccharide | Galectin-3 | Partial signal | NCT04365868: Proportion of patients with new esophageal varices at 78 weeks (registry): belapectin 2 mg/kg 45/119, belapectin 4 mg/kg 51/118 vs placebo 56/118. The sponsor reports that the composite primary endpoint did not reach statistical significance in the intent-to-treat population (n=355); in the pre-defined per-protocol population (n=290), the 2 mg/kg group showed a 48.9% reduction in varices (p<0.05). missed NCT02421094: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) (16 weeks): GR-MD-02 8 mg/kg 19.15 milliseconds (ms) (95% CI -7.7 to 43.5) vs Placebo 1.25 milliseconds (ms) (95% CI -7.7 to 43.5) missed | |
| ALG-055009 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-PNP | Phase 2 | RNA / oligonucleotide | PNPLA3 | Weak signal | No reviewed efficacy summary in this indication | |
| Denifanstat | Phase 2 | Small molecule | Fatty acid synthase (FASN), FASN | Reliable signal | NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45 NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021). | |
| ECC4703 | Phase 2 | — | Thyroid hormone receptor beta (THRβ) | not yet graded | No reviewed efficacy summary in this indication | |
| Efinopegdutide | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Efocipegtrutide | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Ervogastat | Phase 2 | Small molecule | Diacylglycerol acyltransferase 2 (DGAT2) | Partial signal | NCT04321031: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) (Week 48): DGAT2i/PF-06865571 25 mg BID 45% (95% CI 38% to 53%) | DGAT2i/PF-06865571 75 mg BID 48% (95% CI 42% to 55%) | DGAT2i/PF-06865571 150 mg BID 50% (95% CI 43% to 57%) | DGAT2i/PF-06865571 300 mg BID 51% (95% CI 43% to 59%) vs Placebo 38% (95% CI 26% to 50%) NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Gatuzosiran | Phase 2 | RNA / oligonucleotide | HSD17B13 | Weak signal | NCT06104319: Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg) NCT04202354: Treatment-related TEAEs: 0/4 with ARO-HSD 25 mg, 0/4 with 50 mg, 1/4 with 100 mg, and 3/4 with 200 mg versus 0/16 with pooled placebo. | |
| HU6 | Phase 2 | Small molecule | Mitochondrial uncoupling | not yet graded | No reviewed efficacy summary in this indication | |
| Miricorilant | Phase 2 | Small molecule | Glucocorticoid receptor | Weak signal | NCT05117489: Open-label study in patients with presumed non-alcoholic steatohepatitis: patients who received 100 mg of miricorilant orally every Monday and Friday for 12 weeks experienced an approximately 30 percent reduction in liver fat as assessed by MRI-PDFF and showed improvements in liver enzymes and markers of liver disease. | |
| Namodenoson | Phase 2 | — | Adenosine A3 receptor | Partial signal | NCT02927314: Change from baseline in serum ALT at Week 12, namodenoson 25 mg b.d. vs placebo: P=0.066 (trend, not statistically significant) missed | |
| ORMD-0801 | Phase 2 | Peptide | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Rapirosiran (ALN-HSD) | Phase 2 | RNA / oligonucleotide | HSD17B13 | Weak signal | Featured results are safety only in this race | |
| Tipelukast | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | not yet graded | No reviewed efficacy summary in this indication | |
| Vanoglipel | Phase 2 | Small molecule | GPR119 | not yet graded | No reviewed efficacy summary in this indication | |
| VK2809 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | Partial signal | NCT04173065: Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only). NCT02927184: Primary endpoint, placebo-adjusted % change in LDL-C at week 12: VK2809 10mg every-other-day -23.6% (p=0.0121); VK2809 10mg daily -20.2% (p=0.0269); combined VK2809 -21.8% (p=0.0061). | |
| Vonafexor | Phase 2 | Small molecule | Farnesoid X receptor (FXR/NR1H4) | Partial signal | NCT03812029: Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) (12 weeks): Vonafexor 100 mg QD Part B -6.3% (95% CI -8.1 to -4.5) | Vonafexor 200 mg QD Part B -5.4% (95% CI -7.2 to -3.6) vs Placebo Part B -2.3% (95% CI -4 to -0.6) | Placebo Part A 3.9% (95% CI -2.5 to 10.4) | |
| Zabopegdutide | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT06410924: Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. | |
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-PNPLA3 | Phase 1(overall) | RNA / oligonucleotide | PNPLA3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD2389 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BI 3006337 | Phase 1 | — | — | Weak signal | Featured results are safety only in this race | |
| BI 3804379 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ZT003 | Phase 1(overall) | Peptide | FGF21/GLP-1 receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| MGL-2086 | —(overall) | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| NNC4005-001 | —(overall) | RNA / oligonucleotide | SLC25A5 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD7503 | Discontinued | RNA / oligonucleotide | HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| Clesacostat | Discontinued | Small molecule | Acetyl-CoA carboxylase (ACC1/ACC2) | Partial signal | NCT04321031: Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model (Week 48): DGAT2i/PF-06865571 150 mg BID + ACCi/PF-05221304 5 mg BID 23/35 | DGAT2i/PF-06865571 300 mg BID + ACCi/PF-05221304 10 mg BID 19/30 vs Placebo 13/34 | DGAT2i/PF-06865571 25 mg BID 16/35 | DGAT2i/PF-06865571 75 mg BID 25/48 | DGAT2i/PF-06865571 150 mg BID 21/42 | DGAT2i/PF-06865571 300 mg BID 14/31 NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05221304 + PF-06865571 | Discontinued | Small molecule | Acetyl-CoA carboxylase (ACC1/ACC2) + Diacylglycerol acyltransferase 2 | Partial signal | NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Rosiglitazone (Avandia) | Discontinued | Small molecule | PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow survodutide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (2)
2029 (3)
2031 (1)
December 2031 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent